Production (Stage)
MEI Pharma, Inc.
MEIP
$2.18
$0.03081.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 177.05% | -96.73% | |||
| Gross Profit | -177.05% | 96.73% | |||
| SG&A Expenses | -28.44% | -33.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.19% | -57.14% | |||
| Operating Income | 21.19% | 57.14% | |||
| Income Before Tax | 3.88% | 66.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.88% | 66.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.88% | 66.57% | |||
| EBIT | 21.19% | 57.14% | |||
| EBITDA | 21.19% | 53.91% | |||
| EPS Basic | 3.88% | 66.56% | |||
| Normalized Basic EPS | -6.50% | 69.91% | |||
| EPS Diluted | 3.88% | 66.56% | |||
| Normalized Diluted EPS | -6.50% | 69.91% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||